Ascentage Pharma Group International
(NASDAQ) AAPG
Ascentage Pharma Group International Financials at a Glance
Market Cap
$1.77B
Revenue (TTM)
$1.29B
Net Income (TTM)
$1.52B
EPS (TTM)
$-2.01
P/E Ratio
-9.49
Dividend
$0.00
Beta (Volatility)
0.74 (Low)
Dividend
$0.00
Beta (Volatility)
0.74 (Low)
Price
$20.40
Volume
24
Open
$21.40
Price
$20.40
Volume
24
Open
$21.40
Previous Close
$20.40
Daily Range
$20.14 - $21.40
52-Week Range
$17.55 - $48.45
Dividend
$0.00
Beta (Volatility)
0.74 (Low)
Price
$20.40
Volume
24
Open
$21.40
Previous Close
$20.40
Daily Range
$20.14 - $21.40
52-Week Range
$17.55 - $48.45
AAPG News
AAPG: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ascentage Pharma Group International
Industry
Biotechnology
Sector
Health CareEmployees
567
CEO
Da Jan Yang, PhD
Website
www.ascentage.comHeadquarters
Suzhou, 215000, CN
AAPG Financials
Key Financial Metrics (TTM)
Gross Margin
91%
Operating Margin
-3%
Net Income Margin
-3%
Return on Equity
-162%
Return on Capital
-62%
Return on Assets
-38%
Earnings Yield
-10.54%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.77B
Shares Outstanding
92.78M
Volume
24
Short Interest
0.00%
Avg. Volume
3.15K
Financials (TTM)
Gross Profit
$951.57M
Operating Income
$369.73M
EBITDA
$237.63M
Operating Cash Flow
$111.36M
Capital Expenditure
$24.29M
Free Cash Flow
$135.65M
Cash & ST Invst.
$1.24B
Total Debt
$1.67B
Ascentage Pharma Group International Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$233.70M
+63.8%
Gross Profit
$212.05M
+70.3%
Gross Margin
90.74%
N/A
Market Cap
$1.77B
N/A
Market Cap/Employee
$3.13M
N/A
Employees
567
N/A
Net Income
$590.77M
-46.8%
EBITDA
$514.02M
-104.8%
Quarterly Fundamentals
Net Cash
$54.71M
+42.1%
Accounts Receivable
$78.36M
-55.0%
Inventory
$8.59M
+71.0%
Long Term Debt
$882.38M
-30.6%
Short Term Debt
$833.78M
+105.7%
Return on Assets
-38.05%
N/A
Return on Invested Capital
-62.03%
N/A
Free Cash Flow
$0.00
+100.0%
Operating Cash Flow
$0.00
+100.0%